武田(tian)中國(guo)今年新增三(san)款創新藥(yao)(yao)物(wu)(wu)列入《國(guo)家基本醫療保(bao)險、工傷保(bao)險和(he)生育保(bao)險藥(yao)(yao)品(pin)目(mu)錄(2022年)》，包括罕見病(bing)全(quan)球(qiu)創新藥(yao)(yao)拉那利(li)尤單抗(kang)注(zhu)射(she)液、腫(zhong)瘤靶向藥(yao)(yao)物(wu)(wu)布(bu)格替尼片與注(zhu)射(she)用維布(bu)妥(tuo)昔(xi)單抗(kang)，覆蓋遺傳性(xing)(xing)血管性(xing)(xing)水腫(zhong)(Hereditary Angioedema，　HAE)、ALK陽性(xing)(xing)非小細胞肺(fei)癌與CD30陽性(xing)(xing)淋巴瘤疾病(bing)領域，推動規范化診療的臨床實(shi)踐與普及。(醫藥(yao)(yao)健聞(wen))